A Phase 1 Open-label, Multicenter, Dose-Ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1

MC #22-05

NCT #
Condition(s)
Head and Neck Cancer, Lung Cancer (NSCLC), Solid Tumor
Molecular Target(s)
PD-L1
Drug Classification(s)
Immunotherapy
Agents(s)
MT-6402
Phase(s)
I

Mechanism of Action

MT-6402 may bind and kill both tumor and immune PD-L1 expressing cells in a manner consistent with SLTA mediated cellular cytotoxicity through ribosomal inactivation, independent of checkpoint inhibition.

Purpose

  • How much of the study drug can be given with an acceptable level of side effects and the best dosing schedule
  • The effects of the study drug (good and bad)
  • How much of the study drug is absorbed into the blood and how fast it is removed
  • If research tests can be used in the future to predict who will benefit from MT-6402

Location

Mary Crowley Cancer Research - Medical City Dallas

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.

7777 Forest Lane,
Building C-707
Dallas, TX 75230

972.566.3000